Capricor Therapeutics Retains Full Rights to CAP-1002 as Janssen Biotech, Inc. Decides Not to Exercise Option
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: PR Newswire
LOS ANGELES, July 6, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that Janssen Biotech, Inc. (Janssen) has decided not to exercise its option to exclusively license Capricor's lead candidate CAP-1002 (allogeneic cardiosphere-derived cells) for development and commercialization in the field of cardiology. In connection with this decision, the Collaboration Agreement and License Option entered into between Capricor and Janssen has been terminated. As a result, Capricor shall retain all rights to develop and commercialize CAP-1002 for any indication, either independently or in collaboration with third parties. Capricor will also have an irrevocable, fully paid-up non-exclusive license under patents controlled by Janssen utilized in the production of the clinical trial materials manufactured pursuant to the Chemistry, Manufacturing, and Controls (CMC) development plan between Capricor and Janssen and a non-exclusive perpetual license to publish, disclose
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Thinking about buying stock in Curiositystream, Capricor Therapeutics, PowerFleet, Absci, or Nano-X Imaging?PR Newswire
- Capricor Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire
- Earnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts [Yahoo! Finance]Yahoo! Finance
- Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect? [Yahoo! Finance]Yahoo! Finance
CAPR
Earnings
- 2/29/24 - Beat
CAPR
Analyst Actions
- 3/1/24 - HC Wainwright
CAPR
Sec Filings
- 4/1/24 - Form ARS
- 4/1/24 - Form DEF
- 3/20/24 - Form PRE
- CAPR's page on the SEC website